Virpax Pharmaceuticals (VRPX) Stock Price, News & Analysis

Company Overview

Virpax Pharmaceuticals, Inc. (NASDAQ: VRPX) is a specialty pharmaceutical company focused on the development, commercialization and licensing of both branded and generic prescription drugs. The company’s operations center on acquiring, developing and launching solid oral dose products, with an emphasis on analgesics and other high-demand therapeutic categories. Virpax combines in-house formulation expertise with strategic partnerships to advance approved products and pipeline candidates through regulatory review and market introduction.

The Virpax portfolio includes a range of orally administered medications, including immediate-release and extended-release formulations of opioid and non-opioid analgesics. Through a combination of internally filed ANDAs (Abbreviated New Drug Applications) and licensed product rights, the company has built a commercial suite that addresses pain management needs in both acute and chronic settings. Virpax works closely with contract manufacturing organizations and third-party distributors to ensure product availability across retail and institutional channels.

Headquartered in Fort Lauderdale, Florida, Virpax serves patients and healthcare providers throughout the United States. The company’s commercial infrastructure spans national wholesalers, specialty pharmacies and hospital networks, while business development efforts target complementary therapeutic areas and new market segments. Since completing its business combination and listing on the Nasdaq exchange in early 2021, Virpax has pursued a disciplined growth strategy, focusing on timely product launches and ongoing pipeline expansion.

Under the leadership of President and Chief Executive Officer Michael I. P. Grey, Virpax Pharmaceuticals emphasizes operational efficiency, regulatory compliance and strategic licensing arrangements. The management team brings experience from established pharmaceutical firms and contract development and manufacturing organizations, guiding the company’s efforts from initial product concept through post-market support. With a foundation built on a specialized product lineup and targeted commercial execution, Virpax aims to deliver consistent value to patients, partners and shareholders.

Key Stats

• Today's Range: $0.36 to $0.37
• 50-Day Range: $0.22 to $0.46
• 52-Week Range: $0.13 to $60.25
• Volume: 2,201 shs
• Average Volume: 155,144 shs
• Market Capitalization: $448.36 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $75.00
• Consensus Rating: Hold

Virpax Pharmaceuticals Stock Analysis - MarketRank™

Virpax Pharmaceuticals scored higher than 30% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Virpax Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Virpax Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Virpax Pharmaceuticals has a P/B Ratio of 0.22. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.79% of the float of Virpax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virpax Pharmaceuticals has recently increased by 18.15%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Virpax Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Virpax Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.79% of the float of Virpax Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Virpax Pharmaceuticals has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virpax Pharmaceuticals has recently increased by 18.15%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virpax Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.70% of the stock of Virpax Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 32.23% of the stock of Virpax Pharmaceuticals is held by institutions.

VRPX Stock Analysis - Frequently Asked Questions

How have VRPX shares performed this year?

Virpax Pharmaceuticals' stock was trading at $9.4975 at the start of the year. Since then, VRPX shares have decreased by 96.2% and is now trading at $0.3610.

When did Virpax Pharmaceuticals' stock split?

Virpax Pharmaceuticals shares reverse split before market open on Friday, March 1st 2024.The 1-10 reverse split was announced on Friday, March 1st 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Virpax Pharmaceuticals IPO?

Virpax Pharmaceuticals (VRPX) raised $15 million in an initial public offering on Wednesday, February 17th 2021. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity (a division of Fordham Financial Management) acted as the underwriter for the IPO.

How do I buy shares of Virpax Pharmaceuticals?

Shares of VRPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Virpax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Virpax Pharmaceuticals investors own include AMC Entertainment (AMC), Dare Bioscience (DARE), Rallybio (RLYB), Mullen Automotive (MULN), Plug Power (PLUG), SNDL (SNDL) and SOS (SOS).

Company Calendar

• Today: 7/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRPX
• CIK: 1708331
• Web: www.virpaxpharma.com
• Phone: 610-727-4597
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Virpax Pharmaceuticals: $75.00
• High Price Target: $75.00
• Low Price Target: $75.00
• Potential Upside/Downside: +20,716.0%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$15.19 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,554.34%
• Return on Assets: -338.29%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.13
• Quick Ratio: 0.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.65 per share
• Price / Book: 0.22

Miscellaneous

• Outstanding Shares: 1,242,000
• Free Float: 4,707,000
• Market Cap: $447.49 thousand
• Optionable: Not Optionable
• Beta: 1.58